Drug Type Small molecule drug |
Synonyms- |
Action antagonists, inhibitors |
Mechanism A1R antagonists(Adenosine A1 receptor antagonists), FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors), SARS-CoV-2 3CLpro inhibitors(SARS-CoV-2-3C-like-proteinase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC14H8N4O2 |
InChIKeyMQPCQOFUOBENCW-UHFFFAOYSA-N |
CAS Registry371756-64-8 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Cardiovascular Diseases | Preclinical | Saudi Arabia | 14 Oct 2025 | |
| COVID-19 | Preclinical | Saudi Arabia | 14 Oct 2025 | |
| Neoplasms | Preclinical | Saudi Arabia | 14 Oct 2025 | |
| Neurodegenerative Diseases | Preclinical | Saudi Arabia | 14 Oct 2025 |





